| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
AJP - Regulatory, Integrative and Comparative Physiology, Vol 264, Issue 2 460-R465, Copyright © 1993 by American Physiological Society
ARTICLES |
F. A. Le Noble, N. H. Schreurs, H. W. van Straaten, D. W. Slaaf, J. F. Smits, H. Rogg and H. A. Struijker-Boudier
Department of Pharmacology, University of Limburg, Maastricht, The Netherlands.
Angiotensin II acts as a growth factor in the cardiovascular system and has been implicated in angiogenesis. The existence of at least two types of angiotensin II receptors, the AT1 and the AT2 receptors, has been suggested by ligand binding studies. We used three different AT receptor antagonists to study the receptor mediating angiotensin II-induced angiogenesis in the chorioallantoic membrane (CAM) of the chick embryo. Angiotensin II caused pronounced angiogenesis of pre- and postcapillary vessels of 30-40%. This response could only be blocked by adding the peptidergic AT2 antagonist CGP-42112A. The nonpeptidergic AT2 antagonist PD123319 and AT1 antagonist losartan (DuP 753) were not effective. In addition, we used radioligand binding studies with a range of ligands to define the nature of the receptor. Our results show a high density of specific single class AT receptor with a total number of binding sites of 1,190 fmol/mg protein and an affinity constant for angiotensin II of 2.7 nM. The inhibitory concentrations (IC50) for CGP-42112A, PD 123319 and losartan were 724, > 100,000, and 59,000 nM, respectively. Our studies suggest that these binding sites act as receptors for angiotensin II-induced angiogenesis. Both functional and radioligand binding studies suggest that the receptor is different from the classical mammalian AT1 and AT2 receptors.
This article has been cited by other articles:
|
|
 |
|
  L. A. A. Neves, K. Stovall, J. Joyner, G. Valdes, P. E. Gallagher, C. M. Ferrario, D. C. Merrill, and K. B. Brosnihan ACE2 and ANG-(1-7) in the rat uterus during early and late gestation Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R151 - R161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. de Resende, S. L. Amaral, D. H. Munzenmaier, and A. S. Greene Role of endothelial cell apoptosis in regulation of skeletal muscle angiogenesis during high and low salt intake Physiol Genomics, April 13, 2006; 25(2): 325 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jesmin, Y. Hattori, I. Sakuma, C. N. Mowa, and A. Kitabatake Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model Am J Physiol Heart Circ Physiol, October 1, 2002; 283 (4): H1387 - H1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Miyajima, T. Kosaka, T. Asano, T. Asano, K. Seta, T. Kawai, and M. Hayakawa Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogenesis Cancer Res., August 1, 2002; 62(15): 4176 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Segar, G. B. Dalshaug, K. A. Bedell, O. M. Smith, and T. D. Scholz Angiotensin II in cardiac pressure-overload hypertrophy in fetal sheep Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R2037 - R2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. SINN and C. D. SIGMUND Identification of three human renin mRNA isoforms from alternative tissue-specific transcriptional initiation Physiol Genomics, June 29, 2000; 3(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-E. Fabre, A. Rivard, M. Magner, M. Silver, and J. M. Isner Tissue Inhibition of Angiotensin-Converting Enzyme Activity Stimulates Angiogenesis In Vivo Circulation, June 15, 1999; 99(23): 3043 - 3049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sabri, J.-L. Samuel, F. Marotte, P. Poitevin, L. Rappaport, and B. I. Levy Microvasculature in Angiotensin II–Dependent Cardiac Hypertrophy in the Rat Hypertension, August 1, 1998; 32(2): 371 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yang and C. D. Sigmund Developmental expression of human angiotensinogen in transgenic mice Am J Physiol Renal Physiol, May 1, 1998; 274(5): F932 - F939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Munzenmaier and A. S. Greene Opposing Actions of Angiotensin II on Microvascular Growth and Arterial Blood Pressure Hypertension, March 1, 1996; 27(3): 760 - 765. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.-S. Silvestre, S. Bergaya, R. Tamarat, M. Duriez, C. M. Boulanger, and B. I. Levy Proangiogenic Effect of Angiotensin-Converting Enzyme Inhibition Is Mediated by the Bradykinin B2 Receptor Pathway Circ. Res., October 12, 2001; 89(8): 678 - 683. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
